Determinants and stability over time of perception of health risks related to mobile phone base stations

Kowall B, Breckenkamp J, Blettner M, Schlehofer B, Schüz J, Berg-Beckhoff G (2011)
International Journal of Public Health 57(4): 735-743.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Kowall, Bernd; Breckenkamp, JürgenUniBi; Blettner, Maria; Schlehofer, Brigitte; Schüz, Joachim; Berg-Beckhoff, Gabriele
Erscheinungsjahr
2011
Zeitschriftentitel
International Journal of Public Health
Band
57
Ausgabe
4
Seite(n)
735-743
ISSN
1661-8556, 1661-8564
Page URI
https://pub.uni-bielefeld.de/record/2914857

Zitieren

Kowall B, Breckenkamp J, Blettner M, Schlehofer B, Schüz J, Berg-Beckhoff G. Determinants and stability over time of perception of health risks related to mobile phone base stations. International Journal of Public Health. 2011;57(4):735-743.
Kowall, B., Breckenkamp, J., Blettner, M., Schlehofer, B., Schüz, J., & Berg-Beckhoff, G. (2011). Determinants and stability over time of perception of health risks related to mobile phone base stations. International Journal of Public Health, 57(4), 735-743. https://doi.org/10.1007/s00038-011-0310-4
Kowall, Bernd, Breckenkamp, Jürgen, Blettner, Maria, Schlehofer, Brigitte, Schüz, Joachim, and Berg-Beckhoff, Gabriele. 2011. “Determinants and stability over time of perception of health risks related to mobile phone base stations”. International Journal of Public Health 57 (4): 735-743.
Kowall, B., Breckenkamp, J., Blettner, M., Schlehofer, B., Schüz, J., and Berg-Beckhoff, G. (2011). Determinants and stability over time of perception of health risks related to mobile phone base stations. International Journal of Public Health 57, 735-743.
Kowall, B., et al., 2011. Determinants and stability over time of perception of health risks related to mobile phone base stations. International Journal of Public Health, 57(4), p 735-743.
B. Kowall, et al., “Determinants and stability over time of perception of health risks related to mobile phone base stations”, International Journal of Public Health, vol. 57, 2011, pp. 735-743.
Kowall, B., Breckenkamp, J., Blettner, M., Schlehofer, B., Schüz, J., Berg-Beckhoff, G.: Determinants and stability over time of perception of health risks related to mobile phone base stations. International Journal of Public Health. 57, 735-743 (2011).
Kowall, Bernd, Breckenkamp, Jürgen, Blettner, Maria, Schlehofer, Brigitte, Schüz, Joachim, and Berg-Beckhoff, Gabriele. “Determinants and stability over time of perception of health risks related to mobile phone base stations”. International Journal of Public Health 57.4 (2011): 735-743.

8 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Nocebo responses to high-voltage power lines: Evidence from a prospective field study.
Porsius JT, Claassen L, Woudenberg F, Smid T, Timmermans DRM., Sci Total Environ 543(pt a), 2016
PMID: 26599143
Problematic mobile phone use in adolescents: derivation of a short scale MPPUS-10.
Foerster M, Roser K, Schoeni A, Röösli M., Int J Public Health 60(2), 2015
PMID: 25645102
Actual and perceived exposure to electromagnetic fields and non-specific physical symptoms: an epidemiological study based on self-reported data and electronic medical records.
Baliatsas C, Bolte J, Yzermans J, Kelfkens G, Hooiveld M, Lebret E, van Kamp I., Int J Hyg Environ Health 218(3), 2015
PMID: 25704188
Health responses to a new high-voltage power line route: design of a quasi-experimental prospective field study in the Netherlands.
Porsius JT, Claassen L, Smid T, Woudenberg F, Timmermans DR., BMC Public Health 14(), 2014
PMID: 24606914
A web search on environmental topics: what is the role of ranking?
Covolo L, Filisetti B, Mascaretti S, Limina RM, Gelatti U., Telemed J E Health 19(12), 2013
PMID: 24083368

43 References

Daten bereitgestellt von Europe PubMed Central.

A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, Williams MD, Fakiris AJ, McGarry RC, Timmerman RD., Int. J. Radiat. Oncol. Biol. Phys. 76(3), 2009
PMID: 19473777
Subjective symptoms, sleeping problems, and cognitive performance in subjects living near mobile phone base stations.
Hutter HP, Moshammer H, Wallner P, Kundi M., Occup Environ Med 63(5), 2006
PMID: 16621850
Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer.
Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster M, Bazhenova L, Song WY, Mundt AJ., Radiother Oncol 99(1), 2011
PMID: 21429608
Stereotactic single-dose radiotherapy of lung metastases.
Hof H, Hoess A, Oetzel D, Debus J, Herfarth K., Strahlenther Onkol 183(12), 2007
PMID: 18040611
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL., Lung Cancer 49(1), 2005
PMID: 15949595
Mobile phone base stations and adverse health effects: phase 2 of a cross-sectional study with measured radio frequency electromagnetic fields.
Berg-Beckhoff G, Blettner M, Kowall B, Breckenkamp J, Schlehofer B, Schmiedel S, Bornkessel C, Reis U, Potthoff P, Schuz J., Occup Environ Med 66(2), 2009
PMID: 19151228
Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP, Bezjak A., Int. J. Radiat. Oncol. Biol. Phys. 82(2), 2011
PMID: 21377293
Stereotactic ablative radiotherapy for inoperable stage I NSCLC.
Andratschke N., Lancet Oncol. 13(8), 2012
PMID: 22727221
Non-small cell lung cancer: clinical value of new biological predictors.
Graziano SL., Lung Cancer 17 Suppl 1(), 1997
PMID: 9213302
Stereotactic body radiotherapy for lung tumors at the pulmonary hilum.
Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y, Itami J., Strahlenther Onkol 186(5), 2010
PMID: 20437017
Generalized maximally selected statistics.
Hothorn T, Zeileis A., Biometrics 64(4), 2008
PMID: 18325074
Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, Lin S, Zhang X, Tan W, Yu D, Nie S, Miao X, Lin D., J Thorac Oncol 6(11), 2011
PMID: 21841506
Perception of mobile phone and base station risks.
Siegrist M, Earle TC, Gutscher H, Keller C., Risk Anal. 25(5), 2005
PMID: 16297229
Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M., Acta Oncol 45(7), 2006
PMID: 16982542
Stereotactic body radiation therapy (SBRT) for adrenal metastases : a feasibility study of advanced techniques with modulated photons and protons.
Scorsetti M, Mancosu P, Navarria P, Tozzi A, Castiglioni S, Clerici E, Reggiori G, Lobefalo F, Fogliata A, Cozzi L., Strahlenther Onkol 187(4), 2011
PMID: 21437767
Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM., Int. J. Radiat. Oncol. Biol. Phys. 83(4), 2012
PMID: 22417800
Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R., Int. J. Radiat. Oncol. Biol. Phys. 75(3), 2009
PMID: 19251380
Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD., Int. J. Radiat. Oncol. Biol. Phys. 77(4), 2009
PMID: 19800181
Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis.
D'Agostino GR, Autorino R, Pompucci A, De Santis MC, Manfrida S, Di Lella G, Mantini G, Frascino V, Chiesa S, Albanese A, Dinapoli N, Azario L, Fiorentino A, Valentini V, Anile C, Balducci M., Strahlenther Onkol 187(7), 2011
PMID: 21713390
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HJ, Bares R., Eur. J. Nucl. Med. Mol. Imaging 34(4), 2006
PMID: 17103167
Prognosis of surgically resected lung cancer with extremely high preoperative serum carcinoembryonic antigen level.
Takahashi N, Suzuki K, Takamochi K, Oh S., Gen Thorac Cardiovasc Surg 59(10), 2011
PMID: 21984138
Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases.
Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brugel M, Ziegler SI, Molls M, Schwaiger M, Essler M., Strahlenther Onkol 188(7), 2012
PMID: 22441441
Personal exposure to mobile phone frequencies and well-being in adults: a cross-sectional study based on dosimetry.
Thomas S, Kuhnlein A, Heinrich S, Praml G, Nowak D, von Kries R, Radon K., Bioelectromagnetics 29(6), 2008
PMID: 18393264
Public perception of risk concerning celltowers and mobile phones.
Hutter HP, Moshammer H, Wallner P, Kundi M., Soz Praventivmed 49(1), 2004
PMID: 15040130
Stereotactic radiotherapy of targets in the lung and liver.
Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M., Strahlenther Onkol 177(12), 2001
PMID: 11789403
Stereotactic radiotherapy in the liver hilum. Basis for future studies.
Zamboglou C, Messmer MB, Becker G, Momm F., Strahlenther Onkol 188(1), 2011
PMID: 22194027
Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure.
Andratschke N, Zimmermann F, Boehm E, Schill S, Schoenknecht C, Thamm R, Molls M, Nieder C, Geinitz H., Radiother Oncol 101(2), 2011
PMID: 21724287
Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.
Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, Ball DL, Peters LJ., Int. J. Radiat. Oncol. Biol. Phys. 60(2), 2004
PMID: 15380574
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R., J. Clin. Oncol. 27(20), 2009
PMID: 19414667
Choice and interpretation of statistical tests used when competing risks are present.
Dignam JJ, Kocherginsky MN., J. Clin. Oncol. 26(24), 2008
PMID: 18711194
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, Suy S, Yousefi S, Gutierrez CJ, Chang T, Banovac F, Anderson ED, Esposito G, Collins BT., J Hematol Oncol 3(), 2010
PMID: 20132557
18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study.
Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA, Widder J., Eur. J. Nucl. Med. Mol. Imaging 38(6), 2011
PMID: 21210108
Mobile phone base stations and adverse health effects: phase 1 of a population-based, cross-sectional study in Germany.
Blettner M, Schlehofer B, Breckenkamp J, Kowall B, Schmiedel S, Reis U, Potthoff P, Schuz J, Berg-Beckhoff G., Occup Environ Med 66(2), 2008
PMID: 19017702
Electromagnetic hypersensitivity: a systematic review of provocation studies.
Rubin GJ, Das Munshi J, Wessely S., Psychosom Med 67(2), 2005
PMID: 15784787
Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY., Int. J. Radiat. Oncol. Biol. Phys. 83(5), 2012
PMID: 22572078
Molecular and biological factors in the prognosis of non-small cell lung cancer.
Kanters SD, Lammers JW, Voest EE., Eur. Respir. J. 8(8), 1995
PMID: 7489807
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 21987029
PubMed | Europe PMC

Suchen in

Google Scholar